Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
CCL2 mediates cross-talk between cancer cells and stromal fibroblasts that regulates breast cancer stem cells.
It is suggested that CCL2 represents a potential therapeutic target that can block the cancer-host communication that prompts CSC-mediated disease progression and is associated with poor differentiation in primary breast cancers.
Cross-talk between ER and HER2 regulates c-MYC-mediated glutamine metabolism in aromatase inhibitor resistant breast cancer cells
PNRC accumulates in the nucleolus by interaction with B23/nucleophosmin via its nucleolar localization sequence.
SGK3 sustains ERα signaling and drives acquired aromatase inhibitor resistance through maintaining endoplasmic reticulum homeostasis
- Yuan-Zhong Wang, Dujin Zhou, Shiuan Chen
- Biology, MedicineProceedings of the National Academy of Sciences
- 7 February 2017
This study shows that serum- and glucocorticoid-inducible kinase 3 (SGK3), a kinase transcriptionally regulated by ERα in breast cancer, sustains ERα signaling and drives acquired AI resistance, and proposes SGK3 inhibition as a potential effective treatment of acquired AI-resistant breast cancer.
Improvement of sensitivity to tamoxifen in estrogen receptor-positive and Herceptin-resistant breast cancer cells.
- Bin Chen, Yuan-Zhong Wang, S. Kane, Shiuan Chen
- BiologyJournal of molecular endocrinology
- 1 November 2008
The results suggest that the ER genomic pathway in the ER-positive and Herceptin-resistant breast cancer cells may be reactivated, allowing tamoxifen therapy to be effective again, and a combination of tamoxIFen and Sheceptin can be a potential therapeutic strategy for ER- positive and HerCEPTin- resistant human breast cancer.
Molecular Mechanisms of Polybrominated Diphenyl Ethers (BDE-47, BDE-100, and BDE-153) in Human Breast Cancer Cells and Patient-Derived Xenografts.
- N. Kanaya, Lauren Bernal, Shiuan Chen
- Biology, ChemistryToxicological sciences : an official journal of…
- 1 June 2019
According to the results from in vitro experiments, the PBDE congeners regulate distinct nuclear receptor signaling pathways, and a mixture of the three congeners with ratios detected in human serum was tested in an ER+ PDX model.
Coordinated Regulation of Serum- and Glucocorticoid-inducible Kinase 3 by a C-terminal Hydrophobic Motif and Hsp90-Cdc37 Chaperone Complex*
- Yuan-Zhong Wang, Wanping Xu, Dujin Zhou, L. Neckers, Shiuan Chen
- Biology, MedicineThe Journal of Biological Chemistry
- 30 December 2013
This study reports that SGK3 stability and kinase activation are regulated by the Hsp90-Cdc37 chaperone complex, and provides new insights into regulation of SGK 3 stability and activation and the rationale for application of Hsp 90 inhibitors in treating SGk3-dependent cancers.
Down-regulation of programmed cell death 4 (PDCD4) is associated with aromatase inhibitor resistance and a poor prognosis in estrogen receptor-positive breast cancer
- Zhike Chen, Yate-Ching Yuan, Yuan-Zhong Wang, Zheng Liu, H. Chan, Shiuan Chen
- Biology, MedicineBreast Cancer Research and Treatment
- 31 May 2015
Down-regulation of PDCD4 is associated with AI resistance and a poor prognosis in patients with ER-positive breast cancer, and this down-regulation was inversely correlated with activation of HER2 signaling.
SGK3 is an estrogen-inducible kinase promoting estrogen-mediated survival of breast cancer cells.
- Yuan-Zhong Wang, Dujin Zhou, S. Phung, S. Masri, David D. Smith, Shiuan Chen
- BiologyMolecular endocrinology
- 20 April 2011
It is reported thatSGK3 is an estrogen receptor (ER) transcriptional target and promotes estrogen-mediated cell survival of ER-positive breast cancer cells and provides a new link between the PI3K pathway and ER signaling as well as a new estrogen- mediated cell survival mechanism mediated by SGK3 in Breast cancer cells.
SGK3 is an androgen-inducible kinase promoting prostate cancer cell proliferation through activation of p70 S6 kinase and up-regulation of cyclin D1.
This study identifies SGK3 as an AR target and provides a novel androgen-induced cell proliferation mechanism mediated by the AR-SGK3-p70S6K-cyclin D1 pathway in prostate cancer cells.